Quadrant Capital Management LLC raised its position in Gilead Sciences Inc. (NASDAQ:GILD) by 6.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 31,749 shares of the biopharmaceutical company’s stock after buying an additional 1,924 shares during the period. Gilead Sciences makes up 2.2% of Quadrant Capital Management LLC’s holdings, making the stock its 14th largest position. Quadrant Capital Management LLC’s holdings in Gilead Sciences were worth $2,649,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the company. Loomis Sayles & Co. L P boosted its stake in shares of Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 301 shares during the period. North Star Investment Management Corp. boosted its stake in shares of Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock worth $181,000 after buying an additional 700 shares during the period. Peoples Financial Services CORP. boosted its stake in shares of Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock worth $215,000 after buying an additional 600 shares during the period. iAB Financial Bank boosted its stake in shares of Gilead Sciences by 3.3% in the second quarter. iAB Financial Bank now owns 2,750 shares of the biopharmaceutical company’s stock worth $229,000 after buying an additional 87 shares during the period. Finally, BLB&B Advisors LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth $268,000. Institutional investors and hedge funds own 77.96% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.05% during midday trading on Friday, reaching $78.80. 10,307,872 shares of the company were exchanged. The firm has a 50-day moving average of $79.54 and a 200 day moving average of $86.33. The firm has a market capitalization of $103.99 billion, a P/E ratio of 6.92 and a beta of 1.06. Gilead Sciences Inc. has a 52 week low of $76.67 and a 52 week high of $113.31.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The company earned $7.78 billion during the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.15 earnings per share. On average, equities research analysts expect that Gilead Sciences Inc. will post $11.77 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.39%. The ex-dividend date is Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.

GILD has been the topic of a number of recent analyst reports. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Sunday, August 21st. Jefferies Group reiterated a “hold” rating and set a $96.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. Morgan Stanley reiterated a “hold” rating on shares of Gilead Sciences in a report on Sunday, May 29th. RBC Capital Markets reiterated an “outperform” rating and set a $105.00 price target (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Finally, Leerink Swann reiterated a “buy” rating and set a $120.00 price target (down previously from $123.00) on shares of Gilead Sciences in a report on Thursday, June 9th. Nine research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $105.41.

In other news, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $83.12, for a total value of $166,240.00. Following the completion of the sale, the executive vice president now directly owns 63,122 shares in the company, valued at $5,246,700.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider John F. Milligan sold 70,000 shares of the stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now owns 1,128,963 shares of the company’s stock, valued at $87,765,583.62. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.